Written By | Health News Agencies
On June 1, 2026, the FDA approved Xocova (ensitrelvir), the first and only oral drug ever cleared specifically to prevent COVID-19 after someone has already been exposed to it.
Search
HEALTH
Somebody in your house just tested positive for COVID-19. Six years ago, that meant a tense waiting game: mask up, isolate, and hope your immune system held the line. Today, it means something else entirely — a trip to the pharmacy.
On June 1, 2026, the FDA approved Xocova (ensitrelvir), the first and only oral drug ever cleared specifically to prevent COVID-19 after someone has already been exposed to it. Not to treat symptoms once they start. Not to shorten a fever. To stop the infection from ever taking hold in the first place.
Developed by Japanese pharmaceutical giant Shionogi, Xocova is a five-day regimen: three tablets on day one, then one tablet daily through day five. Take it within 72 hours of close contact with an infected person, and according to the clinical trial that won approval, your odds of getting sick drop by more than two-thirds.
The Trial That Changed the Math
The approval rests on a single Phase 3 study called SCORPIO-PEP, published in the New England Journal of Medicine. Researchers enrolled 2,387 people aged 12 and older who lived with someone who had confirmed, symptomatic COVID-19. None had symptoms or tested positive at enrollment.
Half received ensitrelvir. Half got a placebo.
The numbers were stark. By day 10, just 2.9% of those who took ensitrelvir developed symptomatic COVID-19. In the placebo group, that number was 9.0% — a 67% relative risk reduction.
In plain English: if you live with someone who has COVID and take this pill within three days of exposure, you cut your own risk of getting sick by roughly two-thirds.
Side effects occurred at almost identical rates between drug and placebo groups — 15.1% versus 15.5% — with headache, diarrhea, and cough topping the list. No red flags, no signal of serious harm.
How It Actually Works
Ensitrelvir targets the SARS-CoV-2 main protease — an enzyme the virus needs to replicate. Block that enzyme, and the virus can't assemble new particles. No replication, no infection, no illness.
This is different from vaccines, which train your immune system in advance — a process that takes one to two weeks. Ensitrelvir works immediately, regardless of vaccination history.
It's also distinct from Paxlovid, which treats people who already have mild-to-moderate COVID and are at high risk of severe disease. Paxlovid comes with a long list of drug interactions; ensitrelvir doesn't carry that baggage, making it simpler for a broader range of patients.
What the Experts Are Saying
Dr. Frederick Hayden of the University of Virginia called the approval "an important new approach to preventing COVID-19, which continues to impact lives."
Dr. Paul Sax emphasized that the drug's value isn't limited to the unvaccinated or previously uninfected: "XOCOVA offers a new approach to helping prevent COVID-19 after exposure, regardless of prior infection or vaccination status."
Infectious disease specialists stress one caveat: timing is everything. The 72-hour window is not a soft suggestion. Wait too long, and the virus may have already established itself too deeply.
Who Can Actually Get It
Xocova is approved for adults and adolescents 12 and older following close contact with someone who has confirmed COVID-19. Unlike Paxlovid, which is restricted to people at high risk, ensitrelvir's indication applies more broadly — a difference that could dramatically widen the eligible population.
Pricing details are still emerging. Paxlovid lists at over $1,400 for a course, though many patients have accessed it free through government programs. Whether Xocova will see similar assistance remains to be seen.
Why This Matters Even Though "COVID Is Over"
COVID-19 hasn't disappeared — it has settled into a persistent, seasonal presence that still hospitalizes vulnerable people and still produces long-term complications. Each new exposure is another roll of the dice on long COVID.
Household transmission remains one of the virus's most efficient pathways. A tool that can cut that risk by two-thirds isn't a relic of pandemic-era panic — it's a targeted intervention for the exact scenario where COVID still spreads most efficiently: inside our own homes.
Healthcare workers, immunocompromised patients, elderly grandparents, and anyone who cannot afford to lose a week of work all stand to benefit disproportionately.
What This Means for You
If you're exposed to a household member with confirmed COVID-19: speak with a doctor or pharmacist as soon as possible — ideally within hours, and no later than 72 hours after exposure — about whether ensitrelvir is appropriate for you.
It's also worth understanding what this drug is not. It's not a replacement for vaccination. It's not a treatment for people who are already symptomatic — that's still Paxlovid's lane. And it's not a substitute for basic exposure precautions like masking and improving ventilation.
What it is: a genuinely new tool, the first of its kind, arriving at a moment when most of the public had stopped expecting any new COVID innovations at all.
The Bottom Line
Six years into the COVID era, the FDA has approved something the country didn't have before: a pill you take after exposure but before you get sick, with trial data showing it can cut your risk of illness by roughly two-thirds. It won't end COVID. It won't replace vaccines. But for the specific, common moment when someone in your house tests positive and you're waiting to see if you're next, Xocova just changed what "waiting" means.
Sources: Shionogi Inc.; New England Journal of Medicine; FDA announcements via Drugs.com, AJMC, Pharmacy Times, PharmExec; expert commentary via Parade
